VivoSeq
Metabolic & Endocrine

Premature Ovarian Insufficiency

15

Pipeline Programs↗

4

Active Trials↗

10

Companies Involved↗

Premature ovarian insufficiency is an emerging landscape with 15 programs across 10 companies. The most active players are Sclnow Biotechnology Co., Ltd., Roche, Amgen. 2 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

11/100

Mech. Concentration

29/100

Completion Rate

67/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Sclnow Biotechnology Co., Ltd.

1 program

Phase 2Roche logo

Roche

1 program

Phase 2Amgen logo

Amgen

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 3Ferring logo

Ferring

1 program

Phase 3V

Viatris Innovation GmbH

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

17 of 19 classified programs — the dominant modality here.

11%ALL OTHERSMonoclonal antibody15%Protein / enzyme15%

Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 96% of 24 pipeline programs.

Analysis

Trial Status

18

clinical trials

Completed6 · 33%
Unknown status5 · 28%
Recruiting3 · 17%
Suspended2 · 11%
Not yet recruiting1 · 6%
Withdrawn1 · 6%

Clinical Trials

Trial Activity

18 trials

Ventricular Repolarization in Patients With Premature Ovarian Insufficiency (QTIOP)
Recruiting·AAssistance Publique - Hôpitaux de Paris·N/A·NCT04167033·120 enrolled
Clinical Study on the Safety and Efficacy of Human Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency
Recruiting·—·Phase 1/2·NCT07115082·50 enrolled
Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency
Recruiting·Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 3·NCT06851754·185 enrolled
Efficacy and Safety of Huanjingjian Decoction in Women With Premature Ovarian Insufficiency
Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·N/A·NCT07020429·276 enrolled
The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
Completed·—·Phase 2·NCT06117982·11 enrolled
Immunomodulatory Therapy in Women With Autoimmune Premature Ovarian Insufficiency
Completed·—·Phase 2·NCT05586737·15 enrolled
Effect and Mechanism of Jiajian Guishen Formulation on Premature Ovarian Insufficiency Based on Metabolomics
Completed·—·Phase 1·NCT06102655·46 enrolled
Effects of Intraovarian Platelet Rich Plasma in Women With Poor Ovarian Response and Premature Ovarian Insufficiency
Completed·—·N/A·NCT04237909·500 enrolled
Filgrastim for Premature Ovarian Insufficiency
Completed·SSouth Valley University·Phase 4·NCT02783937·10 enrolled
A Case-Control Study of Gut and Vaginal Microbiota Differences Between Premature Ovarian Insufficiency Patients and Healthy Controls
Completed·WWestlake University·N/A·NCT07275671·39 enrolled
A Proof of Concept Study to Evaluate Exosomes From Human Mesenchymal Stem Cells in Women With Premature Ovarian Insufficiency (POI)
Suspended·VVitti Labs, LLC·Phase 1·NCT06072794·9 enrolled
The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
Suspended·SSclnow Biotechnology Co., Ltd.·Phase 2·NCT03816852·12 enrolled
Hormone Replacement for Premature Ovarian Insufficiency
Withdrawn·UUniversity of Pennsylvania·Phase 3·NCT02922348
Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency
Unknown status·—·N/A·NCT05308342·66 enrolled
A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
Unknown status·TTongji Hospital·Phase 1·NCT05522634·100 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)